Brief: Xspray Pharma Says FDA Accepts New Drug Application For Xs003 (Nilotinib)

Xspray Pharma publ AB

21/10/2025 10:52

Oct 21 (Reuters) - XSpray Pharma AB (publ) XSPRAY.ST:

FDA ACCEPTS NEW DRUG APPLICATION FOR XS003 (NILOTINIB) FOR THE TREATMENT OF CML – PDUFA DATE SET FOR JUNE 18, 2026

Source text: ID:nMFN99sVLB

Further company coverage: XSPRAY.ST

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))